GJA1 and breast carcinoma: Using a therapeutic agent, ACT1, that targets endogenous Cx43 by stabilizing its activity at gap junctions, we show that modulation of Cx43 signaling alters breast cancer cell proliferation in the MCF7 and MDA MB 231 cell lines.